Claims for Patent: 10,351,854
✉ Email this page to a colleague
Summary for Patent: 10,351,854
Title: | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Abstract: | This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents. |
Inventor(s): | Brown Bob D., Dudek Henryk T., Lai Cheng |
Assignee: | Dicerna Pharmaceuticals, Inc. |
Application Number: | US15518009 |
Patent Claims: | 2. The dsNA of claim 1 , wherein the sense strand and antisense strand form a duplex such that the antisense strand comprises a two nucleotide overhang at its 3′ end.3. The dsNA of claim 1 , wherein the dsNA comprises a duplex of 19 to 25 base pairs in length.4. The dsNA of claim 2 , wherein the sense strand is 25 to 53 nucleotides in length.5. The dsNA of claim 2 , wherein the sense strand is 36 nucleotides in length and/or wherein the antisense strand is 22 nucleotides in length.6. The dsNA of claim 1 , wherein the sense strand and the antisense strand are each in the range of 21 to 23 nucleotides in length.7. The dsNA of claim 1 , wherein the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.8. The dsNA of claim 7 , wherein the 3′ terminus of the sense strand and the 5′ terminus of the antisense strand form a blunt end.9. The dsNA of claim 1 , wherein the sense strand comprises a tetraloop at its 3′ end.10. The dsNA of claim 6 , wherein the sense strand comprises a tetraloop at its 3′ end.11. The dsNA of claim 9 , wherein the tetraloop comprises a single stranded loop having a sequence of GAAA.12. The dsNA of claim 1 , wherein the dsNA comprises at least one phosphorothioate linkage.13. The dsNA of claim 11 , wherein the dsNA comprises at least one phosphorothioate linkage.14. The dsNA of claim 1 , wherein the one or more modified nucleotides contains a 2′ modification.15. The dsNA of claim 14 , wherein the one or more modified nucleotides are selected from a 2′-O-methyl nucleotide and a 2′-fluoro nucleotide.16. The dsNA of claim 15 , wherein the dsNA comprises at least one 2′-fluoro nucleotide and at least one 2′-O-methyl nucleotide.17. The dsNA of claim 1 , wherein the dsNA is attached to a moiety selected from the group consisting of a GalNAc moiety claim 1 , a cholesterol moiety claim 1 , and a cholesterol targeting ligand.18. The dsNA of claim 15 , wherein the dsNA is attached to a GalNAc moiety.19. A pharmaceutical composition comprising the dsNA of and a pharmaceutically acceptable carrier.21. A mammalian cell containing the nucleic acid of .22. A pharmaceutical composition comprising the nucleic acid of and a pharmaceutically acceptable carrier.24. The dsNA of claim 23 , wherein the complementary region of the antisense strand contains three claim 23 , two claim 23 , or one mismatched nucleotide residues relative to SEQ ID NO: 401.25. The dsNA of claim 23 , wherein the sense strand and antisense strand form a duplex such that the antisense strand comprises a two nucleotide overhang at its 3′ end.26. The dsNA of claim 23 , wherein the dsNA comprises a duplex of 19 to 25 base pairs in length.27. The dsNA of claim 25 , wherein the sense strand is 25 to 53 nucleotides in length.28. The dsNA of claim 25 , wherein the sense strand is 36 nucleotides in length and/or wherein the antisense strand is 22 nucleotides in length.29. The dsNA of claim 23 , wherein the sense strand and the antisense strand are each in the range of 21 to 23 nucleotides in length.30. The dsNA of claim 23 , wherein the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.31. The dsNA of claim 30 , wherein the 3′ terminus of the sense strand and the 5′ terminus of the antisense strand form a blunt end.32. The dsNA of claim 23 , wherein the sense strand comprises a tetraloop at its 3′ end.33. The dsNA of claim 29 , wherein the sense strand comprises a tetraloop at its 3′ end.34. The dsNA of claim 32 , wherein the tetraloop comprises a single stranded loop having a sequence of GAAA. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.